LTR Pharma (ASX:LTP) Operating Cash Flow per Share : A$ (TTM As of Jun. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Operating Cash Flow per Share?

LTR Pharma's operating cash flow per share for the six months ended in Jun. 2023 was A$-0.01. LTR Pharma does not have enough years/quarters to calculate the operating cash flow per share for the trailing twelve months (TTM) ended in Jun. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for LTR Pharma's Operating Cash Flow per Share or its related term are showing as below:

ASX:LTP's 3-Year OCF Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.3
* Ranked among companies with meaningful 3-Year OCF Growth Rate only.

LTR Pharma Operating Cash Flow per Share Historical Data

The historical data trend for LTR Pharma's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Operating Cash Flow per Share Chart

LTR Pharma Annual Data

Trend

Jun21

Jun22

Jun23

Operating Cash Flow per Share

-0.01

LTR Pharma Semi-Annual Data
	Jun21	Jun22	Jun23
Operating Cash Flow per Share	-	-	-0.01

Competitive Comparison of LTR Pharma's Operating Cash Flow per Share

For the Biotechnology subindustry, LTR Pharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LTR Pharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Price-to-Operating-Cash-Flow falls into.

LTR Pharma Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

LTR Pharma's Operating Cash Flow per Share for the fiscal year that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (A: Jun. 2023 )	=	Cash Flow from Operations (A: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (A: Jun. 2023 )
	=	-1.536	/	139.420
	=	-0.01

LTR Pharma's Operating Cash Flow per Share for the quarter that ended in Jun. 2023 is calculated as

Operating Cash Flow per Share (Q: Jun. 2023 )	=	Cash Flow from Operations (Q: Jun. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Jun. 2023 )
	=	-1.536	/	139.420
	=	-0.01

LTR Pharma Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

9A/204 Alice Street, Brisbane, QLD, AUS, 4000

Website

https://www.ltrpharma.com

LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines